VRCA Verrica Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRCA

Price (delayed)

$6.06

Market cap

$104.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.11

Enterprise value

$84.95M

?
Relative Growth: Rel. Growth: 85
Relative Strength: Rel. Strength: 54
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 35

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and ...

Highlights
VRCA's debt has shrunk by 97% YoY and by 12% QoQ
The EPS has soared by 90% year-on-year and by 34% since the previous quarter
The equity has surged by 186% year-on-year but it has declined by 35% since the previous quarter
The quick ratio has increased by 46% YoY but it has decreased by 19% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.verrica.com
Peers: OPK ORGO

Key stats

What are the main financial stats of VRCA

VRCA stock price

How has the Verrica Pharmaceuticals stock price performed over time
Intraday
3.24%
1 week
0.41%
1 month
-4.72%
1 year
1.85%
YTD
-27.08%
QTD
14.56%

Financial performance

How have Verrica Pharmaceuticals's revenue and profit performed over time
Revenue
$37.16M
Gross profit
$33.27M
Operating income
-$13.77M
Net income
-$17.83M
Gross margin
89.5%
Net margin
-48%
Verrica Pharmaceuticals's operating margin has soared by 95% YoY but it has decreased by 8% from the previous quarter
VRCA's net margin has soared by 95% YoY and by 4.6% QoQ
VRCA's operating income has surged by 75% year-on-year but it is down by 13% since the previous quarter
The net income has soared by 73% YoY

Price vs fundamentals

How does VRCA's price correlate with its fundamentals

Growth

What is Verrica Pharmaceuticals's growth rate over time

Valuation

What is Verrica Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.48
P/S
3.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.29
The EPS has soared by 90% year-on-year and by 34% since the previous quarter
The equity has surged by 186% year-on-year but it has declined by 35% since the previous quarter
The stock's price to sales (P/S) is 93% less than its 5-year quarterly average of 48.3 but 30% more than its last 4 quarters average of 2.6
The revenue rose by 4.5% since the previous quarter

Efficiency

How efficient is Verrica Pharmaceuticals business performance
The ROS has soared by 96% year-on-year but it is down by 14% since the previous quarter
The return on assets has surged by 70% year-on-year
The return on invested capital has dropped by 60% since the previous quarter but it has surged by 57% year-on-year

Dividends

What is VRCA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRCA.

Financial health

How did Verrica Pharmaceuticals financials performed over time
Verrica Pharmaceuticals's total assets is 71% higher than its total liabilities
Verrica Pharmaceuticals's total liabilities has plunged by 63% YoY
Verrica Pharmaceuticals's current ratio has surged by 57% YoY but it has decreased by 19% QoQ
VRCA's debt is 91% lower than its equity
The equity has surged by 186% year-on-year but it has declined by 35% since the previous quarter
Verrica Pharmaceuticals's debt to equity has soared by 104% YoY and by 29% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.